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Modified interleukin-2 (IL-2) formulations are being tested in cancer patients. However, IL-2
immunotherapy damages IL-2 receptor (IL-2R)-positive endothelial cells and stimulates IL-
2Rα (CD25)-expressing lymphocytes that curtail anti-tumor responses. A first generation of
IL-2Rβ (CD122)-biased IL-2s addressed some of these drawbacks. Here, we present a
second-generation CD122-biased IL-2, developed by splitting and permanently grafting
unmutated human IL-2 (hIL-2) to its antigen-binding groove on the anti-hIL-2 monoclonal
antibody NARA1, thereby generating NARA1leukin. In comparison to hIL-2/NARA1 com-
plexes, NARA1leukin shows a longer in vivo half-life, completely avoids association with
CD25, and more potently stimulates CD8+ T and natural killer cells. These effects result in
strong anti-tumor responses in various pre-clinical cancer models, whereby NARA1leukin
consistently surpasses the efficacy of hIL-2/NARA1 complexes in controlling metastatic
disease. Collectively, NARA1leukin is a CD122-biased single-molecule construct based on
unmutated hIL-2 with potent efficacy against advanced malignancies.
https://doi.org/10.1038/s41467-020-20220-1 OPEN
1Department of Immunology, University Hospital Zurich, CH-8091 Zurich, Switzerland. 2 Institute of Physiology, University of Zurich, CH-8057
Zurich, Switzerland. 3 Faculty of Medicine, University of Zurich, CH-8006 Zurich, Switzerland. ✉email: onur.boyman@uzh.ch













wing to its ability to stimulate effector-type immune cells,
high-dose interleukin-2 (IL-2) was the first approved
immunotherapy for metastatic cancer. However, IL-2
immunotherapy is limited by dose-dependent adverse events,
which are particularly evident and severe at the high doses
necessary to achieve clinical efficacy1. These adverse effects in
different organs are due to endothelial cell damage, also termed
vascular leak syndrome. Moreover, IL-2 stimulates suppressor-
type immune cells, which in turn curtail anti-tumor effector
cells2–4. Lastly, due to its low molecular weight of 15.5 kDa,
recombinant IL-2 exhibits a short in vivo half-life1. Insight into
the biology of IL-2 and the IL-2 receptor (IL-2R) has provided
possibilities to dissect the beneficial from the unwanted effects of
IL-2.
IL-2 can stimulate several leukocyte subsets, including
suppressor-type CD4+ forkhead box p3 (Foxp3)+ regulatory T
(Treg) cells, cytotoxic CD8+ T cells, and natural killer (NK)
cells5,6. IL-2 exerts its effects through signaling via two different
IL-2Rs. A dimeric IL-2R formed by association of the subunits IL-
2Rβ (CD122) and IL-2Rγ (CD132; also termed common γ chain,
γc) is mainly expressed on antigen-experienced (memory) CD8+
T and NK cells. The addition of a third subunit, named IL-2Rα
(CD25), results in the trimeric IL-2R, which is expressed highly
on CD4+ CD25+ Foxp3+ Treg cells1,7. Upon binding of IL-2,
signal transduction relies on CD122 and γc, whereas CD25 is
dispensable for signaling but instead serves to increase binding
affinity for IL-2.
Association of IL-2 with a specific anti-IL-2 monoclonal anti-
body (mAb), thus forming IL-2/anti-IL-2 mAb complexes (IL-
2cx), can overcome the aforementioned shortcomings of high-
dose IL-28–11. To proceed toward clinical development, we
recently generated and humanized NARA1, a mAb specifically
associating with the CD25-binding site of human IL-2 (hIL-2),
thus acting as a “CD25 mimobody” and forming CD122-biased
hIL-2/NARA1 complexes12. Compared to unbound hIL-2, such
hIL-2/NARA1 complexes prolong the half-life of hIL-2 and
preferentially activate CD122high CD8+ T and NK cells, whereas
association of hIL-2 with CD25-expressing Treg and endothelial
cells is hampered as long as hIL-2 is bound to NARA1. Overall,
these effects result in superior CD8+ T cell-mediated tumor
control in several melanoma mouse models12.
To form hIL-2/NARA1 complexes, hIL-2 and NARA1 are
premixed prior to injection and associate with high affinity
(dissociation constant KD= 1.4 × 10–9M). Although the com-
plexes can be detected in the serum for 24–48 hours, the two
components can dissociate resulting in unbound hIL-2 and
NARA1, which undermines the advantages of hIL-2/NARA1
complexes. Permanent coupling of hIL-2 to NARA1 would pre-
vent in vivo dissociation.
Based on the crystal structure of the hIL-2/NARA1 complex12,
we previously designed, produced, and characterized several
immunocytokine fusion proteins (FPs) where flexible glycine-
serine (GS) linkers connected hIL-2 to the variable region of the
light or heavy chain of NARA113. However, such hIL-2–NARA1
FPs proved challenging to produce and were inferior to hIL-2/
NARA1 complexes in vivo. Thus, we adopted a different strategy,
integrating hIL-2 directly into its antigen-binding groove on
NARA113: We grafted hIL-2 to the complementarity-determining
region 1 of the light chain (L-CDR1) of NARA1, which resulted
in a single and stable molecule termed NARA1leukin.
In this work, we show that NARA1leukin completely abolishes
the binding of hIL-2 to CD25 in vitro and in vivo. Furthermore,
NARA1leukin increases the in vivo half-life of IL-2 and redirects
IL-2’s stimulatory activity to CD122high effector cells translating
to potent anti-cancer responses in several preclinical tumor
models.
Results
Development of NARA1leukin. Based on the 3D-crystal struc-
ture of the hIL-2/NARA1 complex we determined an interaction
site, the B-C loop of hIL-2 and L-CDR1 of humanized NARA1
(hNARA1), which was suitable as an anchoring point. We dis-
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Fig. 1 Design of NARA1leukin. a Graphical representation of strategy followed for generation of NARA1leukin. hIL-2: helix A, green; helix B, yellow; helix C,
dark orange; helix D, pink; and NARA1: heavy chain, blue; light chain, cyan. b Schematic representation of strategy followed for generation of NARA1leukin
showing the engineered protein (color code as in a).
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as well as hNARA1’s L-CDR1 between tyrosine 31 (Y31) and
aspartic acid 34 (D34). Subsequently, we inserted hIL-2 in the
frame of L-CDR1, bridging hNARA1’s Y31 and D34 to hIL-2’s
N77 and K76 residues, respectively (Fig. 1a). To conserve the
non-covalent interactions between hIL-2 and hNARA1, we
replaced the amino acids at positions 32 and 33 of L-CDR1 by
short glycine linkers, (G)4 and (G)3. Moreover, we linked proline
2 (P2) and threonine 133 (T133) at the N- and C-termini of hIL-
2, thereby creating a continuous construct (Fig. 1b). We termed
the resultant molecule NARA1leukin. NARA1leukin was a stable
molecule with minimal aggregate formation upon purification,
which greatly facilitated production.
NARA1leukin avoids CD25-binding and improves
CD122 selectivity in vitro. To assess whether the functional
integrity of hIL-2 was preserved upon engraftment onto
hNARA1, we tested NARA1leukin’s ability to associate with
defined anti-hIL-2 mAbs and recombinant hCD25. To this end,
we devised a sandwich enzyme-linked immunosorbent assay
(ELISA) with the anti-hIL-2 mAbs clone 5344 as capture mAb
(binding hIL-2’s CD122/γc epitope)10,12 and MAB202 as detec-
tion mAb (associating with a hIL-2 region distinct from its IL-2R-
binding epitopes); in this ELISA, NARA1leukin bound with
similar affinity as free hIL-2 and hIL-2/NARA1 complexes
(Fig. 2a). Contrarily, in a sandwich ELISA with plate-bound
recombinant hCD25 and MAB202 as detection mAb, NAR-
A1leukin did not give a signal, even at high concentrations
(Fig. 2b), indicating abolishment of hCD25 binding.
Next, we assessed the ability of NARA1leukin to associate with
and signal via dimeric CD122–γc and trimeric CD25–CD122–γc
IL-2Rs. Upon stimulation with NARA1leukin, human CD8+
T cells and mouse CD8+ T and NK cells showed similar levels of
phosphorylated STAT5 (pSTAT5) compared to free hIL-2 and
hIL-2/NARA1 complexes, while a 30-fold superior stimulation
was noted for human NK cells (Fig. 2c, d). Conversely, the
stimulation of CD4+ CD25+ Treg cells was decreased by 30-fold
for human and by 8000-fold for mouse Treg cells when
stimulated with NARA1leukin compared to hIL-2/NARA1
complexes (Fig. 2c, d), due to lower expression of dimeric
CD122–γc IL-2Rs on Treg cells. Collectively, these data
demonstrate that NARA1leukin exhibits improved in vitro
CD122 bias and CD25 avoidance, when compared to hIL-2/
NARA1 complexes.
NARA1leukin shows prolonged bioactivity and increased
CD122 bias in vivo. Upon a single injection of NARA1leukin to
mice, we observed detectable hIL-2 serum levels up to 72-96
hours, compared to 24–48 hours for hIL-2/NARA1 complexes
(Fig. 3a). In vivo dose escalation studies demonstrated a higher
potency of NARA1leukin in stimulating CD122high cells. The
increase in cell counts and proliferation (as measured by Ki67
positivity) observed with hIL-2/NARA1 complexes was readily
achieved by 4-fold lower doses of hIL-2 in NARA1leukin. The
optimal dose of NARA1leukin was determined to correspond to
0.5 μg hIL-2 equivalent, as higher doses did not further increase
CD8+ T and NK cell expansion but showed a trend toward
toxicity (Supplementary Fig. 1).
To further characterize the in vivo effects of NARA1leukin, we
performed a pharmacodynamic study where pSTAT5, prolifera-
tion, and cell counts were analyzed after a single injection of hIL-
2, hIL-2/NARA1 complexes, and NARA1leukin (Fig. 3b). In mice
receiving NARA1leukin, pSTAT5 signals in CD8+ T and NK cells
persisted steadily for 2 days, unlike hIL-2 and hIL-2/NARA1
complexes where pSTAT5 signals were significantly reduced
already on day 1 (Fig. 3c, d). This activation subsequently
translated to significant expansion of CD8+ T and NK cells,
which correlated with high Ki67 levels indicating vigorous
proliferation (Fig. 3c, d). Contrarily, NARA1leukin did not
induce any pSTAT5 or Ki67 upregulation in CD4+ CD25+ Treg
cells (Fig. 3e), verifying its improved selectivity in vivo.
NARA1leukin improves anti-tumor immune responses. Based
on our aforementioned results, we hypothesized that NAR-
A1leukin should exert anti-tumor effects at lower doses than hIL-
2/NARA1 complexes. In the intradermal B16-F10 melanoma
model, we compared the optimal dose of NARA1leukin (0.5 μg
hIL-2 equivalent) with an equivalent dose (0.5 μg/2.5 μg) and a
three-fold higher dose (1.5 μg/15 μg, corresponding to the optimal
dose12) of hIL-2/NARA1 complexes (Fig. 4a). In this model,
NARA1leukin required less frequent injections and achieved
comparable tumor control at 27% of the total dose of hIL-2/
NARA1 complexes (Fig. 4b, c). To assess the mechanism of
NARA1leukin’s anti-tumor effects, we analyzed the composition
of tumor-infiltrating lymphocytes (TILs) with a particular interest
in the ratio of CD8+ T to CD4+ Foxp3+ Treg cells. Total counts
of CD44+ CD8+ T and NK cells in tumors, tumor-draining
lymph nodes (TDLNs), and spleens were similarly increased in
hIL-2/NARA1 complex- and NARA1leukin-treated animals
(Fig. 4d and Supplementary Fig. 2). However, counts of CD4+
CD25+ Foxp3+ Treg cells were considerably lower in tumors,
TDLNs, and spleens of mice receiving NARA1leukin compared to
hIL-2/NARA1 complexes (Fig. 4d). These changes resulted in a
favorable ratio of CD44+ CD8+ T to Treg cells for NARA1leukin
(Fig. 4e). Although low in numbers, Foxp3+ Treg cells remained
functional in NARA1leukin-treated animals; thus, the depletion
of Treg cells in Foxp3DTR mice by using diphtheria toxin syner-
gized with NARA1leukin therapy to further improve tumor
control (Supplementary Fig. 2).
In animals receiving IL-2 immunotherapy, the majority of
intratumoral CD8+ T cells were CD44+ and expressed high levels
of homing molecules, such as CD62L and CXCR3 (Supplemen-
tary Fig. 2). Tumor-infiltrating CD8+ T cells also showed
decreased abundance of TOX, programmed cell death protein-1
(PD-1), T cell immunoglobulin, mucin domain-3 (TIM-3), and
killer cell lectin-like receptor subfamily G member 1 (KLRG1),
indicating the cells remained functional effector cells (Fig. 5f–i
and Supplementary Fig. 2). These effects were observed with hIL-
2/NARA1 complexes and were even more pronounced with
NARA1leukin.
We did not observe significant IL-2-mediated toxicity in mice
receiving hIL-2/NARA1 complexes or NARA1leukin. Thus,
pulmonary wet weight, as well as serum levels of aspartate
aminotransferase (AST) and alanine aminotransferase (ALT),
remained low and comparable to mice treated with hIL-2/NARA1
complexes (Supplementary Fig. 2).
To compare NARA1leukin with another IL-2-based one-
molecule therapeutic approach, we used H9, which is a CD122-
biased IL-2 mutein14, covalently linked to human Fc (termed H9-
Fc). H9-Fc stimulated CD8+ T cells in vitro to a similar extent as
NARA1leukin and slightly better than hIL-2/NARA1 complexes;
conversely, both H9-Fc and NARA1leukin were better than hIL-2
and hIL-2/NARA1 complexes at avoiding the activation of CD4+
CD25+ T cells, with NARA1leukin being even more selective
than H9-Fc (Supplementary Fig. 3). However, the stimulation of
effector cells in vivo was less pronounced following H9-Fc
compared to hIL-2/NARA1 complexes and NARA1leukin
(Supplementary Fig. 3). In the intradermal B16-F10 melanoma
model, H9-Fc led to a modest reduction of tumor growth, which
was surpassed by hIL-2/NARA1 complexes and NARA1leukin
(Supplementary Fig. 3).
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NARA1leukin immunotherapy reduces metastatic colonization
by circulating tumor cells. As immunotherapies are mainly used
for metastatic malignancies, we tested the therapeutic efficacy of
NARA1leukin in a pulmonary melanoma model where B16-F10
cells were injected intravenously (Fig. 5a). Interestingly, pul-
monary B16-F10 nodules were better controlled by NARA1leukin
treatment, with an overall reduction of pulmonary nodules by
more than 84% compared to PBS, whereas high-dose hIL-2/
NARA1 complexes only achieved 51% reduction (Fig. 5b–d). This
effect led to complete abolishment of lung nodules in 10% of mice
treated with NARA1leukin, whereas high-dose hIL-2/NARA1
complexes did not result in complete clearance pulmonary
nodules. Analysis of immune cells present in pulmonary B16-F10
nodules showed a preferential increase in CD44+ CD8+ T and
NK cells over CD25+ Foxp3+ CD4+ Treg cells (Supplementary
Fig. 4), which was similar to the composition we observed for
cutaneous B16-F10 nodules.
Next, we established a more physiologic metastasis model
where lymph node metastasis is observed in 75% of the untreated
mice after surgical removal of the primary B16-F10 tumor from
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Fig. 2 In vitro characteristics of NARA1leukin. a, b Sandwich ELISA coating anti-hIL-2 mAb 5344 (a) or hCD25 (b) and detecting with anti-hIL-2 mAb
MAB202 shows binding of titrated hIL-2, hIL-2/NARA1 complexes, and NARA1leukin. c, d Phosphorylated STAT5 (pSTAT5) levels of human (c) and
mouse (d) immune cell subsets responding to titrated hIL-2, hIL-2/NARA1 complexes, and NARA1leukin. 1:1 and 2:1 indicate molar ratios of cytokine to
antibody of hIL-2/NARA1 complexes. Dotted lines indicate mean fluorescent intensity (MFI) of pSTAT5 of each cell subset following incubation in media
for 15 min. Half maximal effective concentration (EC50) of each stimulant is presented in the table below. Differences between curves were analyzed using
one-way ANOVA followed by Tukey’s multiple comparison test (c, d). (c) *p= 0.0112, **p= 0.0082, ****p < 0.0001, ***p= 0.0002. (d) ****p < 0.0001,
***p= 0.0001 (hIL-2), ***p= 0.0006 (hIL-2/NARA1). Data are presented as mean ± SD of two (a, b), four (c), or three (d) independent experiments.
Source data are provided as a Source Data file.
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Fig. 3 In vivo characteristics of NARA1leukin. aMice received a single injection of hIL-2 (1 µg), hIL-2/NARA1 complexes (1 µg/5 µg), or NARA1leukin (0.5
µg or 1 µg hIL-2 equivalent). Blood samples were collected at the indicated time points and the presence of hIL-2 in serum was assessed using a sandwich
ELISA coating anti-hIL-2 mAb 5344 and detecting with anti-hIL-2 mAb MAB202. Data are represented as mean ± SD of two independent experiments, n=
2–6 mice/group. b Experimental scheme. Mice received a single injection (arrowhead) of hIL-2 (1.5 µg), hIL-2/NARA1 complexes (1.5 µg/15 µg), or
NARA1leukin (0.5 µg hIL-2 equivalent) and were assessed at indicated time points after the injection (h: hours, d: days). c–e Spleens were analyzed by flow
cytometry to determine pSTAT5, Ki67, and total cell counts of CD8+ T cells (c), CD3- NK1.1+ NK cells (d), and CD4+ CD25+ T cells (e). Differences
between groups at the same time point were analyzed using two-way ANOVA followed by Tukey’s multiple comparison test (c–e). The comparisons of
hIL-2/NARA1 and NARA1leukin to hIL-2 are indicated by asterisks (*), the differences between hIL-2/NARA1 and NARA1leukin are indicated by hashtags
(#) on top of the columns; non-significant p-values are not indicated. (c) ****p < 0.0001, ###p= 0.0002, **p= 0.0082 (d1) **p= 0.0085 (d2) #p=
0.0168. (d) ****p < 0.0001 ***p= 0.0006, ##p= 0.0032 (2 h), *p= 0.0412 (pSTAT5), ##p= 0.013 (d1), ####p < 0.0001, *p= 0.0252 (Ki67) (e) ****p <
0.0001, ####p < 0.0001, **p= 0.0016, *p= 0.0227 (d2), #p= 0.0302, *p= 0.0337 (d4). Data are presented as mean ± SD of three independent
experiments, n= 5 mice/group. Source data are provided as a Source Data file.
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the skin (Fig. 5e). Neoadjuvant treatment with NARA1leukin
prior to surgery abolished metastasis formation in 93% of the
mice, generating the highest survival rate among the different
treatment groups (Fig. 5f).
Furthermore, we assessed the synergistic potential of NAR-
A1leukin with peptide vaccination in a B16-F10 model allowing
observation of both primary and metastatic lesions (Fig. 5g).
Although control of primary tumors was comparable between
high-dose hIL-2/NARA1 complexes and NARA1leukin, lung
nodules were more strongly inhibited by NARA1leukin
(Fig. 5h–j). The combination with peptide vaccination improved
the control of primary tumors with both IL-2 immunotherapies,
with NARA1leukin showing some mild benefit over hIL-2/
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robustly inhibited by NARA1leukin and vaccine combination,
with more than 50% of treated mice showing no evidence of
pulmonary nodules at the endpoint (Fig. 5i, j). Notably,
NARA1leukin monotherapy was able to achieve control of
pulmonary lesions to a comparable extent as combined high-dose
hIL-2/NARA1 complexes with vaccination (Fig. 5i, j).
Efficacy of NARA1leukin against spontaneous metastasis. Our
observations in induced metastatic models led us to direct our
investigations to models that show natural metastatic spreading
of the primary tumors. We assessed the efficacy of NARA1leukin
in the poorly immunogenic Lewis lung carcinoma (LLC) and 4T1
mammary cancer models where spontaneous lung metastases
form following injection of a primary tumor to the skin or
mammary fat pad, respectively. In the LLC model, the progres-
sion of both primary and metastatic lesions were inhibited by
NARA1leukin, with a most impressive effect on lung metastases
(Fig. 6a–f). Thus, 92% of NARA1leukin-treated mice were clear of
metastasis at the endpoint compared to only 8% and 36% for
untreated and hIL-2/NARA1 complex-treated mice, respectively
(Fig. 6d–f).
In the 4T1 tumor model, both IL-2 immunotherapies only
mildly affected the growth of the primary tumor (Fig. 6g–i).
However, NARA1leukin completely inhibited metastasis forma-
tion in almost half of treated mice, whereas the metastatic burden
was only decreased, but not cleared, by treatment with hIL-2/
NARA1 complexes (Fig. 6j–l).
Discussion
To overcome the limitations of high-dose hIL-2 immunotherapy
for metastatic cancer, different avenues have been pursued in the
past years, including the development of muteins of IL-2 or its
receptors as well as association of IL-2 to large molecules14–21.
These approaches aim to increase anti-tumor efficacy and reduce
IL-2-associated adverse effects by directed IL-2R binding, or
targeting to the tumor site, and some of these molecules are
currently in clinical trials17,19–21. Several muteins of hIL-2 have
been generated to ablate the interaction of hIL-2 with CD25.
However, such approaches suffer from reduced stability and/or
short half-life, requiring daily injections or conjugation to a large
molecule, such as an antibody14,22. Moreover, introduced muta-
tions create the risk of immunogenicity and generation of neu-
tralizing anti-drug antibodies (ADAs), which limit the clinical use
of hIL-2 muteins. The hIL-2 mutein BAY 50-479, harboring the
N88R mutation, was the first hIL-2 mutein tested clinically, which
resulted in the generation of ADAs23. Recently a PEGylated IL-2
molecule, termed NKTR-214, has been designed to circumvent
the short half-life of IL-2 and provide selectivity toward the
dimeric IL-2R. Although this molecule provides a kinetically
controlled release of IL-2, PEGylation also interferes with CD122
and γc binding, hampering the stimulation of effector cells21.
Moreover, the large-scale manufacturing of such molecule can be
difficult. To improve the pharmacokinetic properties of hIL-2 and
minimize the stimulation of circulating immune cells, various
immunocytokines have been developed that are made of wild-
type or mutated hIL-2 coupled to targeting antibodies17,19,20.
While linking to antibodies increases the half-life of hIL-2
muteins, this approach also enhances their risk of generating
ADAs. Alternatively, immunocytokines can contain wild-type
hIL-2, however, these do not preferentially stimulate CD122high
effector lymphocytes and can engage with Treg and other
immunosuppressive cells commonly found in the tumor
microenvironment.
A different strategy from the aforementioned FPs and immu-
nocytokines consists in the administration of hIL-2 in the form of
IL-2cx. There, association of a very specific anti-IL-2 mAb with
unmutated hIL-2 forms IL-2cx that result in IL-2R selectivity
in vivo and reduced adverse side effects8,10,11. NARA1 is a
recently-developed anti-hIL-2 mAb that precisely occupies the
CD25-binding epitope of hIL-2; thus hIL-2/NARA1 complexes
lead to preferential stimulation of CD122high effector T and NK
cells12, as well as expand dendritic cells24. Still, as with other
CD122-biasing approaches, hIL-2/NARA1 complexes lead to
detectable stimulation of Treg cells. The herein-presented NAR-
A1leukin is a FP consisting of hIL-2 grafted onto the CDR1 of
hNARA1’s light chain.
When tested in vivo, NARA1leukin further increased stimu-
lation of CD122+ effector-type immune cells over what had been
reported for hIL-2/NARA1 complexes while Treg cells remained
unaffected. This correlated with improved anti-tumor responses,
evident by the ratio of effector to regulatory cells in the tumor
microenvironment. Interestingly, in comparison to hIL-2/NARA1
complexes, NARA1leukin was particularly efficacious in reducing
metastatic tumor lesions. This finding is paramount when
deciding on the preferred CD122-biased IL-2 candidate for
clinical development and treatment of advanced cancer. One
possible mechanism for NARA1leukin’s pronounced property of
reducing the burden metastatic lesions could rely on its exquisite
CD122 bias and thus lack of stimulation of Treg cells. Several
studies have demonstrated that Treg cells promote metastasis
directly by interacting with cancer cells or creating an
Fig. 4 Anti-tumor immune responses generated by NARA1leukin. a Treatment scheme. Mice were injected with 106 B16-F10 melanoma cells
intradermally and treated with PBS, hIL-2/NARA1 complexes (0.5 µg/2.5 µg or 1.5 µg/15 µg, three times a week), or NARA1leukin (0.5 µg hIL-2 equivalent,
two times a week) from day 4 to 14. Spleens, tumor-draining lymph nodes (TDLNs), and tumor-infiltrating lymphocytes (TILs) were analyzed at day 15 by
flow cytometry for the indicated immune cell subsets. b Tumor growth curves of intradermal B16-F10 melanoma until day 15. ****p < 0.0001, ***p=
0.0001. c Change in tumor volumes in individual mice between days 4 and 15. d Cells counts of CD44+ CD8+ T, CD3− CD122+ NK1.1+ NK, and CD4+
CD25+ Foxp3+ Treg cells per mm3 of tumor are indicated. CD8: ***p= 0.001 (NARA1leukin), ***p= 0.0005 (hIL-2/NARA1), *p= 0.0166; NK: **p=
0.0069, ***p= 0.0003; Treg: ****p < 0.0001. e Ratios of CD44+ CD8+ T to CD4+ CD25+ Foxp3+ Treg cells for indicated organs are shown. TILs: *p=
0.0333, **p= 0.0043; TDLNs: ***p= 0.0002, *p= 0.0238 (PBS), *p= 0.0166 (hIL-2/NARA1); Spleen: ***p= 0.0004 (PBS), *p= 0.0389, ***p= 0.0001
(hIL-2/NARA1). f–i Intratumoral CD8+ T cells were analyzed by flow cytometry for CD44 versus TOX (f, g) and PD-1 versus TIM-3 (h, i). Shown are
representative flow cytometry plots (f, h) and percentages (g, i) of CD8+ T cells. g **p= 0.0049, *p= 0.0171. i ****p < 0.0001, **p= 0.0011 (PBS), **p=
0.003 (●), **p= 0.0089 (▲). Data are presented as mean ± SD of four (b–e, h and i) or three (f, g) independent experiments,) n= 15 (PBS and hIL-2/
NARA1 0.5 µg), n= 12 (hIL-2/NARA1 1.5 µg), n= 16 (NARA1leukin) (b), n= 13 (PBS), n= 14 (hIL-2/NARA1 0.5 µg), n= 12 (hIL-2/NARA1 1.5 µg), n= 16
(NARA1leukin) (d, e), n= 7 (PBS), n= 8 (hIL-2/NARA1 0.5 µg/1.5 µg and NARA1leukin) (g), n= 10 (PBS and hIL-2/NARA1 0.5 µg), n= 12 (hIL-2/NARA1
1.5 µg and NARA1leukin) (i) mice/group. Differences between groups at the same time point were analyzed using mixed-effects analysis with
Greenhouse–Geisser correction followed by Tukey’s multiple comparison test (b). Differences in immune cell subsets between groups were analyzed using
Kruskal–Wallis test followed by Dunn’s multiple comparison test (d, e, and g) or by two-way ANOVA followed by Tukey’s multiple comparison test (i). ns,
not significant. Source data are provided as a Source Data file.
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immunosuppressive environment in the primary or distant tumor
site25–29.
The results on NARA1leukin also provide insight into the
mechanism of action of hIL-2/NARA1 complexes by demon-
strating hIL-2 does not need to dissociate from NARA1 to bind
and signal via CD122 and γc. While the design of NARA1leukin
offers clear advantages over hIL-2/NARA1 complexes, such as
irreversible blocking of IL-2’s CD25-binding site and extended
in vivo half-life, the short linker sequences introduced and
structural modifications generated during engraftment of hIL-2
onto NARA1 can serve as neoepitopes that could trigger the
development of ADAs. The question of immunogenicity can only
be addressed in clinical trials and should be noted as a possible
limitation.
Combining NARA1leukin with other anti-cancer therapies
offers attractive options. In this study we report synergistic effects
of NARA1leukin in combination with peptide vaccination, which
improved the control of both primary and metastatic tumors.
Based on this and previous reports on CD122-biased IL-2 for-
mulations, NARA1leukin could be tested together with (i)
immune checkpoint blockers against cytotoxic T-lymphocyte-
associated protein 4, PD-1 and TIM-3; (ii) vaccination; (iii)





































hIL-2/NARA1 (0.5 μg or 1.5 μg)
NARA1leukin (0.5 μg)






















































































































































































ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20220-1
8 NATURE COMMUNICATIONS |         (2020) 11:6440 | https://doi.org/10.1038/s41467-020-20220-1 | www.nature.com/naturecommunications
radiotherapy; and (iv) epigenetic modifying agents1,12,30–34. Also,
the properties of NARA1leukin are suitable for the development
of bispecific antibodies for targeting tumor antigens and provi-
sion of CD122-biased IL-2 signals. Furthermore, the strategy used
to generate NARA1leukin might be applicable to cytokines other
than IL-2, where cytokine/anti-cytokine antibody complexes have
also been reported to exert potent in vivo activity on mouse and
human leukocyte subsets, including IL-1β, IL-3, IL-4, IL-6, IL-7,
IL-15, and granulocyte colony-stimulating factor35–43.
Methods
hIL-2, NARA1, and hIL-2/NARA1 complexes. Human IL-2 (hIL-2; Proleukin)
was purchased from R&D Systems or obtained from the National Cancer Institute’s
Biological Research Branch. hIL-2/NARA1 complexes were generated as previously
described12 and used at 2:1 or 1:1 molar ratios, as indicated. In humanized NARA1
(hNARA1), the variable regions of NARA1 were humanized as previously
described12. We removed critical posttranslational modifications in the CDRs,
designed several sequence variants, and cloned the resulting variable domains of
heavy and light chains into a cytomegalovirus promoter-driven expression plasmid
containing the constant regions of human wild-type IgG1, which were expressed in
human embryonic kidney (HEK) 293 T cells. Sandwich ELISA for hIL-2 binding
was used to select the best combination.
Generation of NARA1leukin. hIL-2 was split between K76 and N77 and was
grafted into the CDR1 of the light chain of hNARA1 between Y31 and D34. Short
gylcine linkers of 3−4 amino acid length were used to link the cytokine to the
antibody. N-terminal half and C-terminal half of hIL-2 was linked to create a
continuous construct. The resulting light chain was synthesized externally and
expressed in HEK293-6E cells together with the parental heavy chain of NAR-
A1leukin. Purification of NARA1leukin was done by affinity chromatography on
Protein A sepharose followed by SEC.
Cell cultures. For protein expression in CHO-S cells, Power CHO-2, ProCHO-4
media and Ultraglutamine (Lonza) were used. Human PBMCs were isolated from
Buffy coats using standard Ficoll density gradient isolation, and maintained in
complete media with 10% fetal bovine serum (FBS), 1% L-glutamine, penicillin-
streptomycin and 1% sodium pyruvate. Murine immune cells were isolated from
C57BL/6 mouse spleens. B16-F10 melanoma, LLC, and CHO-S cell lines were
purchased (ATCC and Thermo Scientific) and cultured in medium, consisting of
advanced DMEM or RPMI 1640 with 10% FBS, 1% L-glutamine, penicillin-
streptomycin, and Fungizone (all from Life Technologies).
Enzyme-linked immunosorbent assay (ELISA). Flat Nunc-Immuno 96-well
plates (Sigma-Aldrich) were coated overnight at 4 °C with capture antibodies in
PBS: purified anti-hIL-2 mAb (clone 5344.111, BD Biosciences) or purified hCD25
(223-2 A/CF, R&D Systems). The plates were then washed with 0.1% Tween 20
(Sigma-Aldrich) and blocked for 1 hour at room temperature (RT) with 1% BSA
(Sigma-Aldrich) in 0.1% Tween 20 at 450 rpm. After washing, titrated doses of hIL-
2, hIL-2/NARA1 (hIL-2 and NARA1 were pre-mixed and incubated for 20 min) or
NARA1leukin were added to plates in blocking solution and incubated for 1 to 2 h
at RT and 450 rpm, followed by washing. For detection, purified biotinylated anti-
hIL-2 mAb (clones MAB202, R&D System) in blocking solution was incubated for
1 h at RT and 450 rpm. Biotinylation was done using the EZ-link Sulfo-NHS.LC
biotinylation kit (Thermo Scientific). Plates were then washed and incubated with
streptavidin-conjugated horseradish peroxidase (BD Biosciences) for 45 minutes at
RT in the dark. Following a final wash, plates were developed using TMB Perox-
idase EIA substrate for 5–10 minutes (BioRad) until the reaction was stopped by
the addition of 1.8 M H2SO4 (Sigma-Aldrich). The plates were read at 450 nm
absorbance using an iMark microplate reader (BioRad).
Protein characterization. Superdex S200 column was used to perform analytical
SEC of purified samples. In total 2–3 µg of the purified proteins were analyzed by
SDS-PAGE using 4–20% NuPAGE Bis-Tris gels (BioRad) in reducing and non-
reducing conditions following manufacturer’s instructions with precision plus
protein dual-color standard (BioRad).
Human Samples. Anonymized buffy coats were obtained from the Swiss Blood
Bank Zurich. The “Fundamental research project for phenotypical and functional
characterization of different leukocyte subsets in healthy and diseased individuals”
(PFCL-1, BASEC no. 2016-01440) project has been reviewed and approved by the
Kantonale Ethikkommission Zurich and has been carried out in accordance with
principles enunciated in the current version of the Declaration of Helsinki, the
guidelines of Good Clinical Practice, and Swiss legal requirements.
STAT5 phosphorylation. Mouse splenocytes or human PBMCs (106 cells/well)
were seeded in 96-well plates and stimulated for 15 min at 37 °C, using hIL-2, hIL-
2/NARA1 complex, or NARA1leukin at equimolar hIL-2 amounts. Cells were
directly fixed with Fix Buffer I (BD) for 10 min at 37 °C followed by permeabili-
zation with Perm Buffer III (BD Phosflow) for 1 h and stained with fluorochrome-
conjugated antibodies in flow cytometry buffer.
Flow cytometry. Single cell suspensions of spleens or lymph nodes (LNs) were
prepared according to standard protocols. Tumors were processed as previously
described12. Briefly, tumors were cut into small pieces, and incubated in 10 ml
dissociation buffer (RPMI, 5% FCS, 10 ug/ml DNAse I (Sigma-Aldrich), and 200
U/ml collagenase type I (Thermo Fisher Scientific) for 60 min at 37 °C and shaking
with 25 rpm. Cell suspensions were then passed through a 70 μm cell strainer, after
one wash a Percoll (40% and 70%; GE Healthcare) gradient centrifugation was
performed. Lungs were passed through a 70 μm cell strainer followed by Percoll
gradient centrifugation. Total cell counts in organs were determined by using a
BioRad TC20 Automated Cell Counter. Dead cells were excluded using Fixable
Viability Dye eFluor™ 780 (eBioscience™). Intracellular, Foxp3, and Ki67 staining
was performed following manufacturer’s instructions. For in vivo pSTAT5 detec-
tion, spleens were directly fixed in Lyse/Fix Buffer (BD Phosflow™) followed by
permeabilization with Perm Buffer III (BD Phosflow) for 1 h. Samples were
acquired on a BD LSR II flow cytometer (BD Biosciences). The data are represented
as percentages of the parent gate or as total cell counts calculated based on fre-
quencies multiplied by the total organ cell counts.
Mice. 2-3-month old female C57BL/6 mice were purchased from Charles River
Laboratories. Balb/c mice were bred in-house and used for experiment at 2-3-
months of age. All mice were kept in specific pathogen-free (SPF) conditions at the
Biologisches Zentrallabor (BZL) where they were maintained at 22 °C and on a 12-
hour light-dark cycle (7 am to 7 pm) and given food and water ad libitum.
Experiments followed the Swiss Federal Veterinary Office guidelines and were
Fig. 5 Anti-tumor efficacy of NARA1leukin against metastatic disease. a Treatment scheme. Mice were injected intravascularly with 3 × 105 B16-F10
melanoma cells and treated with PBS, hIL-2/NARA1 complexes (0.5 µg/2.5 µg or 1.5 µg/15 µg, three times weekly), or NARA1leukin (0.5 µg hIL-2
equivalent, twice weekly) from day 4 to 15. b–d Representative images of the lungs (b), quantification of lung nodules (c), and percentage distributions
according to severity of metastasis categorized by nodule counts (d) are shown for day 18. ****p < 0.0001, **p= 0.0456 (PBS), **p= 0.0024 (hIL-2/
NARA1). e Experimental scheme. Mice were injected with 106 B16-F10 melanoma cells intradermally and treated as described in (a). On day 12 the
intradermal tumor was surgically removed, and mice were observed for 35–50 days for lymph node metastasis. f Metastasis-free survival curves after
surgery. Numbers indicate surviving mice out of total mice at endpoint. ***p= 0.0005, **p= 0.0041. g Experimental scheme. Mice were injected both
intravascularly and intradermally with 3 × 105 and 106 B16-F10 melanoma cells, respectively. Mice were treated with PBS, hIL-2/NARA1 complexes (1.5 µg
/15 µg, three times weekly), or NARA1leukin (0.5 µg hIL-2 equivalent, twice weekly) from day 4 to 14 with or without peptide vaccination given on day 4.
h Tumor growth curves of intradermal B16-F10 melanoma. ****p < 0.0001, **p= 0.0087, *p= 0.0457. i, j Quantification of lung nodules (i) and percentage
distribution according to severity of metastasis categorized by nodule counts (j) are shown for day 15. ****p < 0.0001, ***p= 0.0006. Data are presented
as mean ± SD of three independent experiments, n= 10 (PBS, hIL-2/NARA1 0.5 µg and NARA1leukin), n= 12 (hIL-2/NARA1 1.5 µg) (b–d), n= 16 (PBS and
hIL-2/NARA1 0.5 µg), n= 15 (hIL-2/NARA1 1.5 µg), n= 14 (NARA1leukin) (f), n= 9 (PBS), n= 10 (hIL-2/NARA1, NARA1leukin, and Vaccine), n= 11
(Vaccine+ hIL-2/NARA1 and Vaccine + NARA1leukin) (h–j) mice/group. Differences in nodule counts between groups were analyzed using
Kruskal–Wallis test followed by Dunn’s multiple comparison test (c, i). Differences in survival curves were analyzed by pairwise Mantel-Cox test (f).
Differences between groups at the same time point were analyzed using two-way ANOVA followed by Tukey’s multiple comparison test (h). ns, not
significant. Source data are provided as a Source Data file.
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approved by the Cantonal Veterinary Office. Pre-established exclusion criteria
followed these offices guidelines.
In vivo treatments. All cytokine treatments were injected intraperitoneally. Doses
and schedules used for every experiment are indicated in the figure legends. The
indicated doses correspond to the amount of hIL-2 in free hIL-2, a complex or a
fusion protein. Briefly, the treatments are phosphate-buffered saline (PBS), hIL-2
(1.5 μg, corresponding to 100 μmol), hIL-2/NARA1 complexes as 2:1 (0.5 μg hIL-2
mixed with 2.5μg NARA1 in PBS, corresponding to 33 μmol hIL-2 and 16.7 μmol
NARA1, or 1 μg hIL-2 mixed with 5 μg NARA1, corresponding to 66 μmol hIL-2
and 33 μmol NARA1) or 1:1 molar ratios (1.5 μg hIL-2 with 15 μg NARA1 in PBS,
corresponding to 100 μmol hIL-2 and 100 μmol NARA1) or NARA1leukin (0.5 or
1 μg hIL-2 equivalent, corresponding to 16.7 μmol or 33 μmol NARA1leukin). The
peptide vaccination composed of 70 nmol gp100-peptide (AVGA-
LEGPRNQDWLGVPRQL), 100 μg anti-mouse CD40 antibody (FGK45, BioXCell)
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Tumor models. For the cutaneous melanoma model, 106 B16-F10 melanoma cells
were injected intradermally into the back of syngeneic C57BL/6 mice. For pulmonary
nodules, 3 × 105 B16-F10 melanoma cells were injected intravascular through the tail
vein to syngeneic C57BL/6 mice. 3 × 105 LLC cells were injected intradermally into the
back of syngeneic C57BL/6 mice. Primary LLC tumors were removed surgically after
15 days to observe spontaneous lung metastasis on day 28. 105 4T1 mammary cancer
cells were injected to the mammary fat pad of syngeneic Balb/c mice. Tumor volume
was calculated as follows: V= 2/3 × π × ((a+ b)/4)3, with “a” indicating length and
“b” width of tumor (both in mm). Treatment of mice was started when tumors
became visible and palpable (on day 4 for B16-F10 and LLC, on day 7 for 4T1) and
consisted of 4-6 injections 2-3 times per week of PBS, hIL-2/NARA1 or NARA1leukin,
as indicated. Lungs were stained with Bouin’s solution overnight to better visualize
LLC and 4T1 nodules.
Statistical analyses. Mice were randomly assigned to experimental groups and
results are shown as mean ± SD. Statistical analyses were performed in GraphPad
Prism 8. The details of performed statistical tests are provided in the figure legends.
Comparison of multiple groups with unmatched data were done by Kruskal-Wallis
test followed by Dunn’s multiple comparison test. Comparisons of tumor growth
curves with matched measurements were done either by mixed effects analysis with
Greenhouse-Geisser correction or two-way ANOVA followed by Tukey’s multiple
comparison test.
Software. Flow cytometry data has been collected with BD FACSDivaTM 8.0.1.
Software and analyzed using BD FlowJo 10 and Microsoft Excel 16. Data were
plotted and statistically analyzed using GraphPad Prism 8. Display items were
created using Biorender.com.
Material availability. Materials that are not available commercially can be
requested from the corresponding author.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Data are available within the Article, Supplementary Information or available from the
authors upon request. Source data are provided with this paper.
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